Investment case
Moleculin Biotech, Inc.
MBRX · 3 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 3 macro, policy, and market developments to Moleculin Biotech, Inc. since 2026-09-23. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for MBRX yet, so no modelled value is shown. The MBRX valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run MBRX on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial
Clinical trial progress reduces development risk and moves closer to potential commercialization. Enrollment completion is a key de-risking milestone.
· Moves probability of technical success (pts) for annamycin, time to market for annamycin, future revenue projections for annamycin
What changed, by assumption
- 2026-09-29Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial
- 2026-09-25Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR
- 2026-09-23Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-25 | Share count | Bullish | Company explicitly states it requires significant additional financing to conduct clinical trials, which typically results in equity dilution for biotech firms at this stage. | 0.85 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial | Bullish | 3-12m | 0.80 |
| 2026-09-25 | Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR | Bullish | 1-3m | 0.80 |
| 2026-09-23 | Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 | Bullish | 1-5y | 0.70 |